Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI) Meeting Abstract
| Authors: | Tabernero, J.; Yoshino, T.; Kim, T. W.; Yaeger, R.; Desai, J.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T.; Eng, C.; Tie, J.; Fernandez, M. E. E.; Lonardi, S.; Usari, T.; Hahn, E.; Dychter, S.; Ferrier, G.; Zhang, X.; Kopetz, S. |
| Abstract Title: | Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sept 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S435 |
| End Page: | S436 |
| Language: | English |
| ACCESSION: | WOS:001326612900509 |
| DOI: | 10.1016/j.annonc.2024.08.584 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 515MO -- Source: Wos |
